000739 普洛药业
交易中 05-12 14:06:06
资讯
新帖
简况
普洛药业创60日新高,开源证券一个月前给出“买入”评级
证券之星 · 05-11 16:33
普洛药业创60日新高,开源证券一个月前给出“买入”评级
异动快报:普洛药业(000739)5月11日14点4分触及涨停板
证券之星 · 05-11 14:05
异动快报:普洛药业(000739)5月11日14点4分触及涨停板
股市必读:普洛药业(000739)5月8日董秘有最新回复
证券之星 · 05-11 02:28
股市必读:普洛药业(000739)5月8日董秘有最新回复
普洛药业(000739)披露控股股东股份解除质押公告,5月8日股价上涨0.4%
证券之星 · 05-08
普洛药业(000739)披露控股股东股份解除质押公告,5月8日股价上涨0.4%
普洛药业:公司有布局连续流加氢、电催化等绿色工艺,并且已有多个商业化项目落地
证券之星 · 05-08
普洛药业:公司有布局连续流加氢、电催化等绿色工艺,并且已有多个商业化项目落地
普洛药业(000739)披露关于对下属公司担保的进展公告,5月6日股价下跌2.03%
证券之星 · 05-06
普洛药业(000739)披露关于对下属公司担保的进展公告,5月6日股价下跌2.03%
每周股票复盘:普洛药业(000739)现206.78万元大宗交易
证券之星 · 05-03
每周股票复盘:普洛药业(000739)现206.78万元大宗交易
普洛药业:公司具备在仲丁基锂连续流规模化生产能力
证券之星 · 04-22
普洛药业:公司具备在仲丁基锂连续流规模化生产能力
【机构调研记录】国海富兰克林基金调研普洛药业
证券之星 · 04-22
【机构调研记录】国海富兰克林基金调研普洛药业
【机构调研记录】上银基金调研纳睿雷达、普洛药业等6只个股(附名单)
证券之星 · 04-22
【机构调研记录】上银基金调研纳睿雷达、普洛药业等6只个股(附名单)
【私募调研记录】磐耀资产调研普洛药业、东星医疗
证券之星 · 04-22
【私募调研记录】磐耀资产调研普洛药业、东星医疗
普洛药业(000739)2026年一季报简析:净利润同比增长0.19%,盈利能力上升
证券之星 · 04-22
普洛药业(000739)2026年一季报简析:净利润同比增长0.19%,盈利能力上升
普洛药业(000739.SZ)发布一季度业绩,归母净利润2.49亿元,同比增长0.19%
智通财经 · 04-20
普洛药业(000739.SZ)发布一季度业绩,归母净利润2.49亿元,同比增长0.19%
普洛药业(000739)披露获得氟伐他汀钠缓释片《药品注册证书》,4月16日股价上涨1.18%
证券之星 · 04-16
普洛药业(000739)披露获得氟伐他汀钠缓释片《药品注册证书》,4月16日股价上涨1.18%
普洛药业(000739.SZ)子公司取得氟伐他汀钠缓释片药品注册证书
智通财经 · 04-15
普洛药业(000739.SZ)子公司取得氟伐他汀钠缓释片药品注册证书
普洛药业(000739)披露关于对下属公司担保的进展公告,4月3日股价下跌4.5%
证券之星 · 04-03
普洛药业(000739)披露关于对下属公司担保的进展公告,4月3日股价下跌4.5%
股市必读:普洛药业(000739)4月1日披露最新机构调研信息
证券之星 · 04-02
股市必读:普洛药业(000739)4月1日披露最新机构调研信息
股市必读:普洛药业(000739)3月30日董秘有最新回复
证券之星 · 03-31
股市必读:普洛药业(000739)3月30日董秘有最新回复
普洛药业(000739.SZ)获得药品注册证书及化学原料药上市申请批准通知书
智通财经 · 03-30
普洛药业(000739.SZ)获得药品注册证书及化学原料药上市申请批准通知书
普洛药业:公司目前尚无专治心肌梗死和脑卒中的药物
证券之星 · 03-30
普洛药业:公司目前尚无专治心肌梗死和脑卒中的药物
加载更多
公司概况
公司名称:
普洛药业股份有限公司
所属行业:
医药制造业
上市日期:
1997-05-09
主营业务:
普洛药业股份有限公司的主营业务是创新药研发生产服务(CDMO)、原料药中间体、药品等研发、生产和销售以及进出口贸易业务。公司的主要产品及服务是原料药中间体、创新药研发生产服务、药品、其他。公司荣登“2024年度中国医药工业主营业务收入”第36位;获评国家发改委“先进制造业与现代服务业融合发展试点项目”单位和国家级“绿色工厂”荣誉称号;荣获“中国上市公司百强高成长企业奖”,连续五年在深圳证券交易所上市公司年度信息披露工作评价中获评最高评级A级;荣获2025“上证鹰·金质量”公司治理奖等。
发行价格:
5.70
{"stockData":{"symbol":"000739","market":"SZ","secType":"STK","nameCN":"普洛药业","latestPrice":18.41,"timestamp":1778565966000,"preClose":19.27,"halted":0,"volume":23001708,"delay":0,"changeRate":-0.0446,"floatShares":1158000000,"shares":1158000000,"eps":0.7693,"marketStatus":"交易中","change":-0.86,"latestTime":"05-12 14:06:06","open":19.35,"high":19.48,"low":18.4,"amount":431000000,"amplitude":0.056,"askPrice":18.41,"askSize":26,"bidPrice":18.4,"bidSize":1485,"shortable":0,"etf":0,"ttmEps":0.7693,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1778569200000},"marketStatusCode":2,"adr":0,"adjPreClose":19.27,"symbolType":"stock","openAndCloseTimeList":[[1778549400000,1778556600000],[1778562000000,1778569200000]],"highLimit":21.2,"lowLimit":17.34,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1158443576,"isCdr":false,"pbRate":3.4,"roa":"--","peRate":23.930846,"roe":"3.86%","epsLYR":0.7723,"committee":0.506486,"marketValue":21327000000,"turnoverRate":0.0199,"status":1,"floatMarketCap":21319000000},"requestUrl":"/m/hq/s/000739","defaultTab":"news","newsList":[{"id":"2634409559","title":"普洛药业创60日新高,开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2634409559","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634409559?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:33","pubTimestamp":1778488436,"startTime":"0","endTime":"0","summary":"今日普洛药业创60日新高,收盘报19.27元。2026年3月27日,开源证券研究员余汝意,阮帅发布了对普洛药业的研报《公司信息更新报告:CDMO业绩较快增长,原料药有望见底回升》,该研报对普洛药业给出“买入”评级。研报中预计2026-2028年归母净利润为10.25/12.43/15.21亿元,当前股价对应PE为18.9/15.6/12.8倍,估值性价比高,考虑公司CDMO业务较快增长且在手订单规模较大,维持“买入”评级。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为西部证券的李梦园。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100022023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000739","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634477329","title":"异动快报:普洛药业(000739)5月11日14点4分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2634477329","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634477329?lang=zh_cn&edition=full","pubTime":"2026-05-11 14:05","pubTimestamp":1778479542,"startTime":"0","endTime":"0","summary":"证券之星5月11日盘中消息,14点4分普洛药业触及涨停板。其所属行业化学制药目前上涨。领涨股为南新制药。该股为流感,阿尔茨海默病,创新药概念热股,当日流感概念上涨1.93%,阿尔茨海默病概念上涨1.8%,创新药概念上涨1.72%。5月8日的资金流向数据方面,主力资金净流出850.32万元,占总成交额5.44%,游资资金净流入1329.18万元,占总成交额8.5%,散户资金净流出478.86万元,占总成交额3.06%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100014329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000739","BK0239","BK0188","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634425751","title":"股市必读:普洛药业(000739)5月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2634425751","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634425751?lang=zh_cn&edition=full","pubTime":"2026-05-11 02:28","pubTimestamp":1778437692,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘,普洛药业报收于17.52元,上涨0.4%,换手率0.77%,成交量8.95万手,成交额1.56亿元。投资者: 尊敬的董秘您好,想请问下截止到2026年5月7日,贵公司股东人数是多少?来自公司公告汇总:控股股东横店集团控股有限公司解除质押55,000,000股,占其所持股份比例16.62%,本次解除后其及一致行动人持股无质押。本次解除质押后,控股股东及其一致行动人所持公司股份均无质押情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100001184.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","000739","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633431617","title":"普洛药业(000739)披露控股股东股份解除质押公告,5月8日股价上涨0.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633431617","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633431617?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:40","pubTimestamp":1778233232,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘,普洛药业报收于17.52元,较前一交易日上涨0.4%,最新总市值为202.96亿元。该股当日开盘17.5元,最高17.64元,最低17.27元,成交额达1.56亿元,换手率为0.77%。普洛药业股份有限公司于近日收到控股股东横店集团控股有限公司通知,其将所持有的55,000,000股公司股份办理了解除质押登记手续,占其所持股份比例的16.62%,占公司总股本的4.75%。本次解除质押后,控股股东及其一致行动人所持公司股份均无质押情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800031779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000739","BK0188","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633433913","title":"普洛药业:公司有布局连续流加氢、电催化等绿色工艺,并且已有多个商业化项目落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2633433913","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633433913?lang=zh_cn&edition=full","pubTime":"2026-05-08 16:06","pubTimestamp":1778227579,"startTime":"0","endTime":"0","summary":"证券之星消息,普洛药业(000739)05月08日在投资者关系平台上答复投资者关心的问题。投资者提问:3. 氮杂环丁烷小环结构是抗癌、神经、抗病毒创新药的核心骨架,请问贵公司在该类高难度小环中间体领域,是否有布局连续流加氢、电催化等绿色工艺?目前有没有已落地的商业化项目?普洛药业回复:投资者您好!公司很多项目中都具有单杂环丁烷等小环结构;公司有布局连续流加氢、电催化等绿色工艺,并且已有多个商业化项目落地。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800027008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0060","BK0239","000739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633189790","title":"普洛药业(000739)披露关于对下属公司担保的进展公告,5月6日股价下跌2.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633189790","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633189790?lang=zh_cn&edition=full","pubTime":"2026-05-06 18:24","pubTimestamp":1778063072,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘,普洛药业报收于17.9元,较前一交易日下跌2.03%,最新总市值为207.36亿元。该股当日开盘18.3元,最高18.7元,最低17.71元,成交额达2.63亿元,换手率为1.26%。近日,普洛药业发布《关于对下属公司担保的进展公告》。上述担保事项已经公司第九届董事会第十九次会议及2025年年度股东会审议通过,属于公司对下属子公司的融资担保,累计担保余额为384,748万元,占公司2025年度经审计净资产的60.70%,担保对象均为下属子公司,无逾期担保。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600032138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","000739","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632674145","title":"每周股票复盘:普洛药业(000739)现206.78万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2632674145","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632674145?lang=zh_cn&edition=full","pubTime":"2026-05-03 03:15","pubTimestamp":1777749313,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,普洛药业(000739)报收于18.27元,较上周的18.35元下跌0.44%。本周,普洛药业4月28日盘中最高价报19.35元。4月30日盘中最低价报17.93元。普洛药业当前最新总市值211.65亿元,在化学制药板块市值排名23/150,在两市A股市值排名1011/5200。本周关注点来自交易信息汇总:普洛药业4月27日发生206.78万元大宗交易交易信息汇总4月27日普洛药业现206.78万元大宗交易以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300000624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000739","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629909743","title":"普洛药业:公司具备在仲丁基锂连续流规模化生产能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2629909743","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629909743?lang=zh_cn&edition=full","pubTime":"2026-04-22 15:03","pubTimestamp":1776841393,"startTime":"0","endTime":"0","summary":"证券之星消息,普洛药业(000739)04月22日在投资者关系平台上答复投资者关心的问题。投资者提问:目前行业内在仲丁基锂连续流规模化生产上已出现明显技术领先企业,该技术直接决定高难度创新药分子的可开发性与商业化效率。请问公司是否掌握相关核心工艺?有无具体项目案例、产能规模及客户验证?若存在明显技术代差,将如何应对高端订单流失的风险?普洛药业回复:投资者您好!公司具备在仲丁基锂连续流规模化生产能力,已有项目案例,并得到了客户验证。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200030119.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000739","BK0239","BK0060","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629648560","title":"【机构调研记录】国海富兰克林基金调研普洛药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2629648560","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629648560?lang=zh_cn&edition=full","pubTime":"2026-04-22 08:13","pubTimestamp":1776816824,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及4月21日披露的机构调研信息,国海富兰克林基金近期对1家上市公司进行了调研,相关名单如下:1)普洛药业 个股亮点:公司积极开展大语言模型与生成式AI应用,其AIGC平台已正式上线并开发近300个Agent,提升了流程自动化与决策智能化水平。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200015154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","000739","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629064813","title":"【机构调研记录】上银基金调研纳睿雷达、普洛药业等6只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629064813","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629064813?lang=zh_cn&edition=full","pubTime":"2026-04-22 08:13","pubTimestamp":1776816794,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及4月21日披露的机构调研信息,上银基金近期对6家上市公司进行了调研,相关名单如下:1)纳睿雷达 个股亮点:子公司天津希格玛微电子,主要致力于光电传感器、MCU芯片、触摸芯片和电源管理芯片等数字、模拟和数模混合的专用集成电路的研发、设计和销售。后续进展均以公司在上交所披露的信息为准。金赛药业贡献收入98.19亿元,百克生物亏损扩大。H股上市申请失效,后续将审慎推进。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200015114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","688522","BK0239","BK0188","BK0214","000739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629648500","title":"【私募调研记录】磐耀资产调研普洛药业、东星医疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2629648500","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629648500?lang=zh_cn&edition=full","pubTime":"2026-04-22 08:12","pubTimestamp":1776816772,"startTime":"0","endTime":"0","summary":"根据市场公开信息及4月21日披露的机构调研信息,知名私募磐耀资产近期对2家上市公司进行了调研,相关名单如下:1)普洛药业 个股亮点:公司积极开展大语言模型与生成式AI应用,其AIGC平台已正式上线并开发近300个Agent,提升了流程自动化与决策智能化水平。在投资方法上,磐耀资产注重研究驱动的投资,强调严谨科学的投资流程在投资中的重要性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026042200015053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301290","000739","BK0188","BK0060","BK0251","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629066332","title":"普洛药业(000739)2026年一季报简析:净利润同比增长0.19%,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2629066332","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629066332?lang=zh_cn&edition=full","pubTime":"2026-04-22 06:13","pubTimestamp":1776809633,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期普洛药业发布2026年一季报。截至本报告期末,公司营业总收入24.47亿元,同比下降10.36%,归母净利润2.49亿元,同比上升0.19%。本报告期普洛药业盈利能力上升,毛利率同比增幅22.02%,净利率同比增幅11.87%。去年的净利率为9.1%,算上全部成本后,公司产品或服务的附加值一般。持有普洛药业最多的基金为信澳健康中国混合A,目前规模为3.54亿元,最新净值2.37,较上一交易日下跌0.5%,近一年上涨16.52%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200011547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628743307","title":"普洛药业(000739.SZ)发布一季度业绩,归母净利润2.49亿元,同比增长0.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628743307","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628743307?lang=zh_cn&edition=full","pubTime":"2026-04-20 16:34","pubTimestamp":1776674094,"startTime":"0","endTime":"0","summary":"智通财经APP讯,普洛药业(000739.SZ)发布2026年第一季度报告,第一季度,公司实现营业收入24.47亿元,同比下降10.36%。归属于上市公司股东的净利润2.49亿元,同比增长0.19%。归属于上市公司股东的扣除非经常性损益的净利润2.43亿元,同比增长18.15%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430654.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627296455","title":"普洛药业(000739)披露获得氟伐他汀钠缓释片《药品注册证书》,4月16日股价上涨1.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627296455","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627296455?lang=zh_cn&edition=full","pubTime":"2026-04-16 17:42","pubTimestamp":1776332543,"startTime":"0","endTime":"0","summary":"截至2026年4月16日收盘,普洛药业报收于18.06元,较前一交易日上涨1.18%,最新总市值为209.21亿元。该股当日开盘17.96元,最高18.18元,最低17.72元,成交额达1.46亿元,换手率为0.7%。普洛药业控股子公司浙江普洛康裕制药有限公司近日收到国家药品监督管理局签发的氟伐他汀钠缓释片《药品注册证书》,规格为80mg,批准文号为国药准字H20263882,视同通过仿制药一致性评价。2025年度国内市场规模约为0.29亿片,销售金额约1.19亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600032205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0060","BK0239","000739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627040934","title":"普洛药业(000739.SZ)子公司取得氟伐他汀钠缓释片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2627040934","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627040934?lang=zh_cn&edition=full","pubTime":"2026-04-15 16:29","pubTimestamp":1776241761,"startTime":"0","endTime":"0","summary":"智通财经APP讯,普洛药业(000739.SZ)公告,公司控股子公司浙江普洛康裕制药有限公司(简称“康裕制药”)收到国家药品监督管理局签发的氟伐他汀钠缓释片《药品注册证书》。氟伐他汀是一个全合成的降胆固醇药物,是羟甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂,可与HMG-CoA还原酶竞争,抑制HMG-CoA转化为3-甲基-3,5-二羟戊酸,而3-甲基-3,5-二羟戊酸是甾醇包括胆固醇的前体物质。本品的作用部位主要在肝脏,具有抑制内源性胆固醇的合成,降低肝细胞内胆固醇的含量,刺激低密度脂蛋白(LDL)受体的合成,提高LDL微粒的摄取,降低血浆总胆固醇浓度的作用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","000739","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624659025","title":"普洛药业(000739)披露关于对下属公司担保的进展公告,4月3日股价下跌4.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624659025","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624659025?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:54","pubTimestamp":1775210055,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,普洛药业报收于17.6元,较前一交易日下跌4.5%,最新总市值为203.89亿元。近日,普洛药业股份有限公司披露《关于对下属公司担保的进展公告》。公告显示,公司于2026年3月13日至3月26日期间,与多家银行签订担保合同,为旗下四家子公司提供合计14,500万元的连带责任保证担保。上述担保事项已履行董事会及股东大会审议程序。截至目前,公司对下属子公司的担保余额为382,348万元,占2025年度经审计净资产的60.32%,无逾期担保。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300034784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK0188","000739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624061548","title":"股市必读:普洛药业(000739)4月1日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2624061548","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624061548?lang=zh_cn&edition=full","pubTime":"2026-04-02 00:53","pubTimestamp":1775062390,"startTime":"0","endTime":"0","summary":"截至2026年4月1日收盘,普洛药业报收于18.41元,上涨3.25%,换手率0.85%,成交量9.88万手,成交额1.81亿元。一季报将于4月21日披露。宠物CDMO业务受益于全球动物保健需求增长及战略客户合作深化,预计持续增长。CDMO收入确认依据合同条款及会计准则执行,视项目情况判断时点。关于媒体报道CDMO一季度同比增长100%,公司回应称部分产线情况不完全代表整体,具体数据以定期报告和公告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200000649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0060","000739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623340257","title":"股市必读:普洛药业(000739)3月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2623340257","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623340257?lang=zh_cn&edition=full","pubTime":"2026-03-31 00:50","pubTimestamp":1774889421,"startTime":"0","endTime":"0","summary":"截至2026年3月30日收盘,普洛药业报收于17.88元,上涨1.88%,换手率0.87%,成交量10.1万手,成交额1.81亿元。董秘最新回复投资者: 你好,近期猝死新闻时间频发,张雪峰事件让更多人注意到心肌梗死和脑卒中的年轻化趋势,请问普洛药业在涉及心肌梗死、脑卒中方面有无原料药产品供应?当日关注点来自交易信息汇总:3月30日主力资金净流入85.0万元,显示主力对普洛药业短期走势持积极态度。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033100002295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000739","BK0060","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623979123","title":"普洛药业(000739.SZ)获得药品注册证书及化学原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2623979123","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623979123?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:15","pubTimestamp":1774858530,"startTime":"0","endTime":"0","summary":"智通财经APP讯,普洛药业(000739.SZ)发布公告,近日,公司控股子公司浙江普洛康裕制药有限公司收到国家药品监督管理局签发的硫酸麻黄碱注射液《药品注册证书》以及硫酸麻黄碱原料药的《化学原料药上市申请批准通知书》。公司的硫酸麻黄碱注射液属于国内首家获批上市,视同通过仿制药一致性评价。该药品适用于治疗麻醉状态下发生的具有临床意义的低血压。本次硫酸麻黄碱化学原料药批准上市和硫酸麻黄碱注射液取得药品注册证书,体现了公司原料药制剂一体化的协同策略,将有利于提升产品的市场竞争力,也将进一步丰富公司产品管线,对公司经营发展具有一定的积极作用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421702.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"普洛药业(000739.SZ)获得药品注册证书及化学原料药上市申请批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000739","BK0188","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623397899","title":"普洛药业:公司目前尚无专治心肌梗死和脑卒中的药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2623397899","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623397899?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:00","pubTimestamp":1774857623,"startTime":"0","endTime":"0","summary":"证券之星消息,普洛药业03月30日在投资者关系平台上答复投资者关心的问题。心脑血管治疗领域一直是公司重点布局的方向,公司已有多个心脑血管类产品,同时还有十多个产品处于研发过程中;但公司目前尚无专治心肌梗死和脑卒中的药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000018879.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK0188","000739"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778565969350,"stockEarnings":[{"period":"1week","weight":0.0547},{"period":"1month","weight":0.0949},{"period":"3month","weight":0.0541},{"period":"6month","weight":0.262},{"period":"1year","weight":0.4714},{"period":"ytd","weight":0.1992}],"compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":0.0599},{"period":"3month","weight":0.0234},{"period":"6month","weight":0.0562},{"period":"1year","weight":0.2642},{"period":"ytd","weight":0.0645}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"普洛药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"33720人(较上一季度减少1.29%)","perCapita":"34341股","listingDate":"1997-05-09","address":"浙江省金华市东阳市横店江南路399号","registeredCapital":"115844万元","survey":" 普洛药业股份有限公司的主营业务是创新药研发生产服务(CDMO)、原料药中间体、药品等研发、生产和销售以及进出口贸易业务。公司的主要产品及服务是原料药中间体、创新药研发生产服务、药品、其他。公司荣登“2024年度中国医药工业主营业务收入”第36位;获评国家发改委“先进制造业与现代服务业融合发展试点项目”单位和国家级“绿色工厂”荣誉称号;荣获“中国上市公司百强高成长企业奖”,连续五年在深圳证券交易所上市公司年度信息披露工作评价中获评最高评级A级;荣获2025“上证鹰·金质量”公司治理奖等。","listedPrice":5.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"普洛药业(000739)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供普洛药业(000739)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"普洛药业,000739,普洛药业股票,普洛药业股票老虎,普洛药业股票老虎国际,普洛药业行情,普洛药业股票行情,普洛药业股价,普洛药业股市,普洛药业股票价格,普洛药业股票交易,普洛药业股票购买,普洛药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"普洛药业(000739)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供普洛药业(000739)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}